Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives

Cancer Treatment Reviews

Volumn 35, Issue 5, 2009, Pages 451-462

  Scartozzi, Mario ^a   Bittoni, Alessandro ^a,c   Pistelli, Mirco ^a,c   Galizia, Eva ^b,c   Berardi, Rossana ^a,c   Giampieri, Riccardo ^a,c   Faloppi, Luca ^a,c   Cascinu, Stefano ^a,c  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Ospedale Profili   (Italy)

^c NONE

Author keywords

Gastric cancer; Molecular biology; Predictive factors; Prognostic factors

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CARBOPLATIN; CELECOXIB; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; DOXIFLURIDINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; GLUTATHIONE TRANSFERASE; IRINOTECAN; MARIMASTAT; METHOTREXATE; MITOMYCIN C; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; PACLITAXEL; PLACEBO; PROTEIN BCL 2; PROTEIN P53; SURVIVIN; THYMIDINE PHOSPHATE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRASTUZUMAB; UFT;

ADVANCED CANCER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER RESISTANCE; CHEMOSENSITIVITY; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GASTROINTESTINAL TOXICITY; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; HETEROZYGOSITY LOSS; HUMAN; LUNG NON SMALL CELL CANCER; MICROSATELLITE INSTABILITY; NEUROTOXICITY; OVERALL SURVIVAL; PANCREAS CANCER; PHARMACOGENETICS; PROGNOSIS; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL RATE; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 68049087844     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.04.008     Document Type: Review

References (111)

1. Cunningham D., Allum W., Stenning S., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
2. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-730
3. Longley D.B., Harkin D.P., and Johnston P.G. 5-Fluorouracil: mechanism of action and clinical strategies. Nat Rev Cancer 3 (2003) 330-338
4. Lenz H.J., Leichman C.G., Danenberg K.D., et al. Thymidilate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumour response and overall survival. J Clin Oncol 14 (1996) 176-182
5. Johnston P.G., Lenz H.J., Leichman C.G., et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55 (1995) 1407-1412
6. Boku N., Chin K., Hosokawa K., et al. Biological markers as predictor of response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 4 (1998) 1469-1474
7. Yeh K.H., Shun C.T., Chen C.L., et al. High expression of thymidilate synthase is associated with drug resistance of gastric adenocarcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82 (1998) 1626-1631
8. Terashima M., Fujiwara H., Takagane A., et al. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer 6 (2003) 71-81
9. Kwon H.C., Roh M.S., Oh S.Y., et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18 (2007) 504-509
10. Kawakami K., Omura K., Kanehira E., et al. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19 (1999) 3249-3252
11. Kawakami K. Watanabe G: identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63 (2003) 6004-6007
12. Ruzzo A., Graziano F., Kawakami K., et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24 (2006) 1883-1891
13. Mandola M.V., Stoehlmacher J., Zhang W., et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14 (2004) 319-327
14. Keam B., Im S.A., Han S.W., et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study, comprehensive analysis of polymorphisms as a predictive, prognostic marker. BMC Cancer 8 (2008) 148
15. Hua D., Huang Z.H., Mao Y., et al. Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouraci-based adjuvant chemotherapy for gastric cancer. World J Gastroenterol 13 (2007) 5030-5034
16. Kono A., Hara Y., Sugata S., et al. Activation of 50-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 31 (1983) 175-178
17. Nishida M., Hino A., Mori K., et al. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 19 (1996) 1407-1411
18. Miyadera K., Sumizawa T., Haraguchi M., et al. Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 55 (1995) 1687-1690
19. Kakeji Y., Maehara Y., Shibahara K., et al. Heterogeneity and clinical role of thymidine phosphorylase activity in gastric cancer. Oncol Rep 6 (1999) 1213-1216
20. Maeda K., Chung Y.S., Ogawa Y., et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer 73 (1996) 884-888
21. Tanigawa N., Amaya H., Matsumura M., et al. Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma. Cancer Lett 108 (1996) 281-290
22. Koizumi W., Saigenji K., Nakamaru N., et al. Prediction of response to 50-deoxy-5-fluorouridine (50-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor. Oncology 56 (1999) 215-222
23. Terashima M., Fujiwara H., Takagane A., et al. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancers patients. Eur J Cancer 38 (2002) 2375-2381
24. Nishina T., Hyodo I., Miyaike J., et al. The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5′-deoxy-5-fluorouridine. Eur J Cancer 40 (2004) 1566-1571
25. Napieralski R., Ott K., Kremer M., et al. Combined GADD45 and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 11 (2005) 3025-3031
26. Kodera Y., Ito S., Fujiwara M., et al. Gene expression of 5-fluorouracil metabolic enzymes in primarygastric cancer: correlation with drug sensitivity against 5-fluorouracil. Cancer Lett 252 (2007) 307-313
27. Kono A., Hara Y., Sugata S., et al. Activation of 50-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull (Tokyo) 31 (1983) 175-178
28. Koizumi W., Okayasu I., Hyodo I., et al. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Anticancer Drugs 19 (2008) 819-824
29. Diasio R.B., and Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16 (1989) 215-237
30. Etienne M.C., Lagrange J.L., Dassonville O., et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12 (1994) 2248-2253
31. Lu Z., Zhang R., and Diasio R.B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53 (1993) 5433-5438
32. Johnson M.R., Hageboutros A., Wang K., et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5 (1999) 2006-2011
33. Milano G., Etienne M.C., Pierrefite V., Barberi-Heyob M., Deporte-Fety R., and Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79 (1999) 627-630
34. Terashima M., Irinoda T., Fujiwara H., et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 22 (2002) 761-768
35. Terashima M. Genetic polymorphisms related to fluoropyrimidine sensitivity and toxicity. Gan To Kagaku Ryoho 35 (2008) 1101-1104
36. Grau J.J., Caballero M., Monzò M., et al. Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. J Surg Oncol 98 (2008) 130-134
37. Ichikawa W., Uetake H., Shirota Y., et al. Both gene expression for orotate phosphoribosyl transferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89 (2003) 1486-1492
38. Adlard J.W., Richman S.D., Seymour M.T., et al. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 3 (2002) 75-82
39. Taomoto J., Yoshida K., Wada Y., et al. Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines. Oncology 70 (2006) 458-464
40. Mizutani Y., Wada H., Fukushima M., et al. Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. Cancer 100 (2004) 723-731
41. Isshi K., Sakuyama T., Gen T., et al. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5FU. Int J Clin Oncol 7 (2002) 335-342
42. Sakurai Y., Kamoshida S., Furuta S., et al. Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues. Gastric Cancer 10 (2007) 234-240
43. Sakurai Y., Furuta S., Sunagawa R., et al. Orotate phosphoribosyltransferase levels in gastric carcinoma and normal gastric mucosa - correlation with thymidylate synthase and dihydropyrimidine dehydrogenase levels and the changes after neoadjuvant chemotherapy. Gan To Kagaku Ryoho 34 (2007) 1581-1587
44. Sakurai Y., Kamoshida S., Furuta S., et al. Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy. Gan To Kagaku Ryoho 35 (2008) 1147-1155
45. Smith M.L., Chen I.T., Zhan Q., et al. Interaction of the p53-regulated protein GADD45 with proliferating cell nuclear antigen. Science 266 (1994) 1376-1380
46. Pinto A.L., and Lippard S.J. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta 780 (1985) 167-180
47. McHugh P.J., Sones W.R., Hartley J.A., et al. Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol Cell Biol 20 (2000) 3425-3433
48. Smith M.L., Kontny H.U., Bortnick R., et al. The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. Exp Cell Res 230 (1997) 61-68
49. Tew K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54 (1994) 4313-4320
50. Nishimura T., Newkirk K., Sessions R.B., et al. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 2 (1996) 1859-1865
51. Tsuchida S., and Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 27 (1992) 337-384
52. Goto S., Iida T., Cho S., et al. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res 31 (1999) 549-558
53. Bai F., Nakanishi Y., Kawasaki M., et al. Immunohistochemical expression of glutathione S-transferase-pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Cancer 78 (1996) 416-421
54. Oguri T., Fujiwara Y., Katoh O., et al. Glutathione S-transferase-pi gene expression and platinum drug exposure in human lung cancer. Cancer Lett 156 (2000) 93-99
55. Stoehlmacher J., Park D.J., Zhang W., et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91 (2004) 344-354
56. London S.J., Yuan J.M., Chung F.L., et al. Isothiocyanates glutathione S-transferase M1, T1 polymorphisms, lung cancer risk: a prospective study of men in Shangai, China. Lancet 356 (2000) 2104
57. Stoehlmacher J., Park D.J., Zhang W., et al. Association between glutathione StransferaseP1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94 (2002) 936-942
58. Stoehlmacher J., Park D.J., Zhang W., et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91 (2004) 344-354
59. Watters J.W., and McLeod H.L. Cancer pharmacogenomics: current and future application. Biochim Biophys Acta 1603 (2003) 99-111
60. Goekkurt E., Hoehn S., Wolschke C., et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) - novel predictors for response and survival in gastric cancer patients. Br J Cancer 94 (2006) 281-286
61. Joshi M.B., Shirota Y., Danenberg K.D., et al. High gene expression of TS1, GSTP1 and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11 (2005) 2215-2221
62. Ott K., Lordick F., and Becker K. Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Int J Colorectal Dis 23 (2008) 773-782
63. Schuler M., and Green D.R. Mechanism of p53 dependent apoptosis. Biochem Soc Trans 29 (2001) 684-688
64. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
65. Lowe S.W., Ruley H.E., Jacks T., et al. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993) 957-967
66. Cascinu S., Graziano F., Del Ferro E., et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 83 (1998) 1917-1922
67. Nakata B., Chung K.H., Ogawa M., et al. P53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg Today 28 (1998) 595-598
68. Nagashima F., Boku N., Ohtsu M., et al. Biological markers as a predictor for cytotoxicity of anticancer agents. Cell 74 (1993) 957-967
69. Nagashima F., Boku N., Ohtsu M., et al. Response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol 35 (2005) 714-719
70. Bartek J., Bartkova J., Vojtesek B., et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 5 (1991) 1699-1703
71. Bataille F., Rümmele P., Dietmaier W., et al. Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. J Clin Pathol Mol Pathol 56 (2003) 286-292
72. Sullivan A., Syed N., Gasco M., et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23 (2004) 3328-3337
73. Huang Z.H., Hua D., Li L.H., et al. Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. Cancer Res Clin Oncol 134 (2008) 1129-1134
74. Tahara M., Ochiai A., Fujimoto J., et al. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. Oncol Rep 11 (2004) 9-15
75. Lu C.D., Altieri D.C., Tanigawa N., et al. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58 (1998) 1808-1812
76. Carles D., Sylvic I., Pierre J.S., et al. Expression of class III tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92 (2005) 25-30
77. Urano N., Fujiwara Y., Doki Y., et al. Clinical significance of class III ß-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 28 (2006) 375-381
78. Worm J., and Guldberg P. DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy. J Oral Pathol Med 31 (2002) 443-449
79. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 94 (2006) 179-183
80. Weisenberger D.J., Siegmund K.D., Campan M., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38 (2006) 787-793
81. Kang G.H., Lee S., Kim W.H., et al. Epstein-Barr viruspositive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol 160 (2002) 787-794
82. Van Rijnsoever M., Elsaleh H., Joseph D., et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 9 (2003) 2898-2903
83. An C., Choi I.S., Yao J.C., et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 11 (2005) 656-663
84. Napieralski R., Ott K., Kremer M., et al. Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features. Clin Cancer Res 13 (2007) 5095-5102
85. Rhyu M.G., Park W.S., and Meltzer S.J. Microsatellite instability occurs frequently in human gastric carcinoma. Oncogene 9 (1994) 29-32
86. Fleisher A.S., Esteller M., Wang S., et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 59 (1999) 1090-1095
87. Wu M.S., Lee C.W., Shun C.T., et al. Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. Genes Chromosomes Cancer 27 (2000) 403-411
88. Grundei T., Vogelsang H., Ott K., et al. Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma. Clin Cancer Res 6 (2000) 4782-4788
89. Aebi S., Kurdi-Haidar B., Gordon R., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56 (1996) 3087-3090
90. Ott K., Vogelsang H., Mueller J., et al. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 9 (2003) 2307-2315
91. Sakai K., Mori S., Kawamoto T., et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 77 (1986) 1047-1052
92. Tapia C., Glatz K., Novotny H., et al. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. J Natl Cancer Inst 77 (1986) 1047-1052
93. Ross J.S., and McKenna B.J. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19 (2001) 554-568
94. Roh J.K., Paik S., Chung H.C., et al. Overexpression of erbB-2 protein in gastric adenocarcinoma - a potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen. Gan To Kagaku Ryoho 19 (1992) 1207-1219
95. Tanner M., Hollmén M., Junttila T.T., et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16 (2005) 273-278
96. Rebischung C., Barnoud R., and Stéfani L. The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. Gastric Cancer 8 (2005) 249-252
97. Inui T., Asakawa A., Morita Y., et al. HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. J Intern Med 260 (2006) 484-487
98. Honda M., Mori M., Ueo H., et al. Stability of a stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA. Gut 39 (1996) 444-448
99. Alakus H., Grass G., Hennecken J.K., et al. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histol Histopathol 23 8 (2008) 917-923
100. Kimata M., Otani Y., Kubota T., et al. Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. Jpn J Cancer Res 93 (2002) 834-841
101. Tierney G.M., Griffin N.R., Stuart R.C., et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 35 (1999) 563-568
102. Bramhall S.R., Hallissey S.T., Whiting J., et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86 (2002) 1864-1870
103. Sun W.H., Yu Q., Shen H., et al. Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis. World J Gastroenterol 10 (2004) 2809-2813
104. Joo Y.E., Oh W.T., Rew J.S., et al. Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion 66 (2002) 222-229
105. Uefuji K., Ichikura T., and Mochizuki H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 76 (2001) 26-30
106. Murata H., Kawano S., Tsuji S., et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 94 (1999) 451-455
107. Cho S.J., Kim N., Kim J.S., et al. The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. Dig Dis Sci 52 (2007) 1713-1721
108. Wu Y.L., Fu S.L., Zhang Y.P., et al. Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts. Biomed Pharmacother 59 (2005) S289-S292
109. Kim N., Kim C.H., Ahn D.W., et al. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. J Gastroenterol Hepatol 24 (2009) 480-487
110. Altorki N.K., Keresztes R.S., Port J.L., et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21 (2003) 2645-2650
111. Milella M., Gelibter A., Di Cosimo S., et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 101 (2004) 133-138